Martin Shkreli, former CEO of Vyera Pharmaceuticals, has been ordered by a court to return almost $65 million in profits that he and his company made from monopolizing the market for the lifesaving drug Daraprim. The anti-parasite drug is used to prevent and treat parasitic infections from the Toxoplasma gondii parasite as well as malaria, and Shkreli played a pivotal role in leading the company's fight against generic competitors while he was in prison.